Syed Ali Tayyeb Hasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Syed Ali Tayyeb Hasan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Daniyal Ali Khan
Medical College, Aga Khan University, Karachi, Pakistan
4 shared publications - Mahnoor Khan
Medical College, Shaikh Khalifa Bin Zayed Al Nahyan Medical & Dental College, Lahore, Pakistan
4 shared publications - Kantesh Kumar
Centre of Excellence for Trauma and Emergencies The Aga Khan University Karachi Sindh Pakistan
3 shared publications - Shahzaib Khan
Division of Internal Medicine, Department of Medicine, Rutgers Health Community Medical Center, Toms River, US
3 shared publications - Ali Bin Abdul Jabbar
Department of Medicine, Creighton University School of Medicine, Omaha, USA
2 shared publications - Fatima Najam
Division of Internal Medicine, Department of Medicine, Jefferson Abington Hospital, Abington, US
2 shared publications
Latest Publications
- 8 January 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 5
Epidemiologic Trends in Secondary Malignant Neoplasms of the Liver in the United States: A 25-Year National Study
Purpose Secondary malignant neoplasms of the liver are more common than primary liver cancers but remain understudied. This study provides the first nationwide analysis of liver metastases-related mortality trends and disparities in the US. Methods This study analyzed CDC WONDER mortality data (1999–2023) and US Cancer Statistics incidence data for adults ≥ 45 years. Liver metastases-related (ICD-10: C78.7) mortality was stratified by demographics, geographic regions, and primary site of malignancy. Age-adjusted mortality and incidence rates (AAMRs, AAIRs) and crude mortality rates (CMRs) were reported per 100,000 population. Temporal trends were analyzed using Joinpoint regression to calculate annual and average annual percentage changes (APC, AAPC). Results Liver metastases-related AAMR rose from 23.8 (1999) to 25.1 (2023) (AAPC = 0.22%*, 95% CI: 0.14–0.29). Males accounted for 51.3% of the 597,332 deaths and had higher AAMRs than females throughout. Lung (25.6%) and colon (24.6%) cancers were the leading primary sites causing deaths related to liver metastases. AAIRs and AAMRs (irrespective of metastasis) declined for most primary cancers. CMRs had an increasing trend, with nearly a 10-fold difference between ages 45–54 and 85+. Non-Hispanic (NH) Blacks had the highest AAMR with a declining trend (AAPC=-0.66%*), while NH Whites saw a significant increase (AAPC = 0.49%*). The West showed the biggest regional increase (AAPC = 1.24%*). AAMR rose the most in Vermont (AAPC = 5.30%*). Rural areas consistently had higher AAMRs (1999–2020). Conclusion Mortality from liver metastases has risen among older US adults, with notable demographic and geographic disparities. Improved survival among patients with primary cancers means more individuals are living long enough to experience recurrence and develop late liver metastases, underscoring the need for enhanced detection, surveillance, and management.
- 8 January 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 5
Epidemiologic Trends in Secondary Malignant Neoplasms of the Liver in the United States: A 25-Year National Study
Purpose Secondary malignant neoplasms of the liver are more common than primary liver cancers but remain understudied. This study provides the first nationwide analysis of liver metastases-related mortality trends and disparities in the US. Methods This study analyzed CDC WONDER mortality data (1999–2023) and US Cancer Statistics incidence data for adults ≥ 45 years. Liver metastases-related (ICD-10: C78.7) mortality was stratified by demographics, geographic regions, and primary site of malignancy. Age-adjusted mortality and incidence rates (AAMRs, AAIRs) and crude mortality rates (CMRs) were reported per 100,000 population. Temporal trends were analyzed using Joinpoint regression to calculate annual and average annual percentage changes (APC, AAPC). Results Liver metastases-related AAMR rose from 23.8 (1999) to 25.1 (2023) (AAPC = 0.22%*, 95% CI: 0.14–0.29). Males accounted for 51.3% of the 597,332 deaths and had higher AAMRs than females throughout. Lung (25.6%) and colon (24.6%) cancers were the leading primary sites causing deaths related to liver metastases. AAIRs and AAMRs (irrespective of metastasis) declined for most primary cancers. CMRs had an increasing trend, with nearly a 10-fold difference between ages 45–54 and 85+. Non-Hispanic (NH) Blacks had the highest AAMR with a declining trend (AAPC=-0.66%*), while NH Whites saw a significant increase (AAPC = 0.49%*). The West showed the biggest regional increase (AAPC = 1.24%*). AAMR rose the most in Vermont (AAPC = 5.30%*). Rural areas consistently had higher AAMRs (1999–2020). Conclusion Mortality from liver metastases has risen among older US adults, with notable demographic and geographic disparities. Improved survival among patients with primary cancers means more individuals are living long enough to experience recurrence and develop late liver metastases, underscoring the need for enhanced detection, surveillance, and management.
- Open Access
- 16 October 2025
- Published by Springer Nature in Research Square
Temporal Trends and Disparities in Nontuberculous Mycobacterial Mortality Among Older Adults in the United States: A CDC WONDER Analysis
Introduction Nontuberculous mycobacteria (NTM) are increasingly recognized as significant pathogens, particularly in older and immunocompromised individuals, yet national data on NTM-associated mortality trends are limited and rely on older cohorts. Materials and Methods This cross-sectional study used CDC WONDER data (1999–2023) to assess NTM-related (ICD-10: A31) mortality trends in U.S. adults aged ≥ 45. Trends were stratified by gender, age, race, urbanization status, region, state, and place of death. Age-adjusted and crude mortality rates (AAMRs, CMRs) were calculated per million population. Trends were analyzed using Joinpoint regression to estimate annual and average annual percent changes (APCs, AAPCs). Results NTM-related mortality increased significantly from 1999 to 2023, with AAMR rising from 5.1 to 7.0 per million (AAPC = 1.38%*, 95% CI: 0.77–1.99). Of the 15,626 deaths, females accounted for 51.7%. However, males had higher AAMRs throughout. CMRs greatly increased across age groups, with the ≥ 85 cohort demonstrating the highest burden and rise in mortality (AAPC = 2.66%*, 95% CI: 2.03–3.49). White and Hispanic groups both demonstrated significantly rising AAMRs over time, with Black adults being the only group demonstrating the reverse trend (AAPC = − 1.40%*, 95% CI: − 2.44 to − 0.14). All regions except the West showed rising AAMRs, led consistently by the South, which increased from 6.2 to 8.6 (AAPC = 1.32%*, 95% CI: 0.69–1.85). Hawaii (12.2), South Carolina (9.8), and Vermont (9.0) recorded the highest AAMRs. Urban areas consistently exhibited higher AAMRs than rural ones. Conclusion NTM mortality is rising, with marked disparities by age, gender, race, and geography, underscoring the need for targeted public health interventions.
- 16 October 2025
- Published by Springer Nature in Research Square
Open AccessTemporal Trends and Disparities in Nontuberculous Mycobacterial Mortality Among Older Adults in the United States: A CDC WONDER Analysis
Introduction Nontuberculous mycobacteria (NTM) are increasingly recognized as significant pathogens, particularly in older and immunocompromised individuals, yet national data on NTM-associated mortality trends are limited and rely on older cohorts. Materials and Methods This cross-sectional study used CDC WONDER data (1999–2023) to assess NTM-related (ICD-10: A31) mortality trends in U.S. adults aged ≥ 45. Trends were stratified by gender, age, race, urbanization status, region, state, and place of death. Age-adjusted and crude mortality rates (AAMRs, CMRs) were calculated per million population. Trends were analyzed using Joinpoint regression to estimate annual and average annual percent changes (APCs, AAPCs). Results NTM-related mortality increased significantly from 1999 to 2023, with AAMR rising from 5.1 to 7.0 per million (AAPC = 1.38%*, 95% CI: 0.77–1.99). Of the 15,626 deaths, females accounted for 51.7%. However, males had higher AAMRs throughout. CMRs greatly increased across age groups, with the ≥ 85 cohort demonstrating the highest burden and rise in mortality (AAPC = 2.66%*, 95% CI: 2.03–3.49). White and Hispanic groups both demonstrated significantly rising AAMRs over time, with Black adults being the only group demonstrating the reverse trend (AAPC = − 1.40%*, 95% CI: − 2.44 to − 0.14). All regions except the West showed rising AAMRs, led consistently by the South, which increased from 6.2 to 8.6 (AAPC = 1.32%*, 95% CI: 0.69–1.85). Hawaii (12.2), South Carolina (9.8), and Vermont (9.0) recorded the highest AAMRs. Urban areas consistently exhibited higher AAMRs than rural ones. Conclusion NTM mortality is rising, with marked disparities by age, gender, race, and geography, underscoring the need for targeted public health interventions.
- Open Access
- 16 September 2025
- Published by Springer Nature in Research Square
Epidemiologic Trends in Secondary Malignant Neoplasms of the Liver in the United States: A 25-Year National Study
Background Secondary malignant neoplasms of the liver (SMNL) are more common than primary liver cancers but remain understudied. This study provides the first nationwide analysis of SMNL mortality trends and disparities in the US. Methods This study analyzed SMNL-related (ICD-10: C78.7) CDC WONDER mortality data (1999–2023), and US Cancer Statistics incidence data for adults ≥ 45 years, stratified by demographics, geography, and primary site. Age-adjusted mortality and incidence rates (AAMRs, AAIRs) and crude mortality rates (CMRs) were reported per 100,000 population. Temporal trends were analyzed using Joinpoint regression. Results SMNL-related AAMR rose from 23.8 (1999) to 25.1 (2023). Males accounted for 51.3% of the 597,332 deaths and had higher AAMRs than females throughout. Lung (25.6%) and colon (24.6%) cancers were the leading primary sites causing SMNL-related deaths. AAIRs and AAMRs (irrespective of metastasis) declined for most primary cancers. CMRs progressively increased across each successive 10-year age group. Non-Hispanic (NH) Blacks had the highest AAMR but with a declining trend, while NH Whites saw a significant increase. West’s AAMRs showed the biggest increase. Rural areas consistently had higher AAMRs. Conclusions SMNL mortality is rising among older US adults, with disparities. Improved primary cancer survival extends the window for metastatic progression, highlighting the need for better detection and management.
- 16 September 2025
- Published by Springer Nature in Research Square
Open AccessEpidemiologic Trends in Secondary Malignant Neoplasms of the Liver in the United States: A 25-Year National Study
Background Secondary malignant neoplasms of the liver (SMNL) are more common than primary liver cancers but remain understudied. This study provides the first nationwide analysis of SMNL mortality trends and disparities in the US. Methods This study analyzed SMNL-related (ICD-10: C78.7) CDC WONDER mortality data (1999–2023), and US Cancer Statistics incidence data for adults ≥ 45 years, stratified by demographics, geography, and primary site. Age-adjusted mortality and incidence rates (AAMRs, AAIRs) and crude mortality rates (CMRs) were reported per 100,000 population. Temporal trends were analyzed using Joinpoint regression. Results SMNL-related AAMR rose from 23.8 (1999) to 25.1 (2023). Males accounted for 51.3% of the 597,332 deaths and had higher AAMRs than females throughout. Lung (25.6%) and colon (24.6%) cancers were the leading primary sites causing SMNL-related deaths. AAIRs and AAMRs (irrespective of metastasis) declined for most primary cancers. CMRs progressively increased across each successive 10-year age group. Non-Hispanic (NH) Blacks had the highest AAMR but with a declining trend, while NH Whites saw a significant increase. West’s AAMRs showed the biggest increase. Rural areas consistently had higher AAMRs. Conclusions SMNL mortality is rising among older US adults, with disparities. Improved primary cancer survival extends the window for metastatic progression, highlighting the need for better detection and management.
- Open Access
- 15 September 2025
- Published by Springer Nature in Research Square
Tuberculosis Trends, Disparities, and Forecasts in the United States: Will the 2035 Elimination Goal Be Met?
Background Tuberculosis (TB) remains a US public health concern, with persistent disparities, yet TB-related mortality trends, especially among older adults, remain understudied. Methods This cross-sectional study analysed CDC-WONDER mortality data (1999–2023) and National Notifiable Diseases Surveillance System incidence data (1999–2022) for adults aged ≥ 45 years. TB (ICD-10: A16-A19) incidence rates (IRs), age-adjusted and crude mortality rates (AAMRs, CMRs) were calculated per million population. Trends were analysed using Joinpoint regression, and ARIMA models were used to forecast mortality through 2035 in the context of the US elimination target. Results From 1999–2022, TB IRs declined from 64.3 to 25.0 per million. AAMRs fell from 17.4 to 7.5 between 1999–2023 (AAPC = -3.36%, 95% CI: -3.72 to -2.98). Of 26,341 deaths, 62.5% were male. By 2023, AAMRs in both genders had declined by over half. CMRs decreased across all age groups, with the largest decline in those ≥ 85 years, who also had the highest rates. Asian/Pacific Islander and American Indian/Alaska Native populations consistently had the highest AAMRs, while White individuals had the lowest. All regions except the West showed steady declines. Alaska, Hawaii, California, Mississippi, and Texas had the highest AAMRs. Large metropolitan areas consistently had higher AAMRs. Most deaths were due to respiratory TB, and 65.2% occurred in inpatient hospitals. Forecasting indicated that AAMRs are projected to remain above the US elimination threshold by 2035. Conclusion TB-related mortality in the US has declined over two decades, but recent resurgence and persistent demographic and geographic disparities highlight the need for targeted interventions to achieve elimination.
- 15 September 2025
- Published by Springer Nature in Research Square
Open AccessTuberculosis Trends, Disparities, and Forecasts in the United States: Will the 2035 Elimination Goal Be Met?
Background Tuberculosis (TB) remains a US public health concern, with persistent disparities, yet TB-related mortality trends, especially among older adults, remain understudied. Methods This cross-sectional study analysed CDC-WONDER mortality data (1999–2023) and National Notifiable Diseases Surveillance System incidence data (1999–2022) for adults aged ≥ 45 years. TB (ICD-10: A16-A19) incidence rates (IRs), age-adjusted and crude mortality rates (AAMRs, CMRs) were calculated per million population. Trends were analysed using Joinpoint regression, and ARIMA models were used to forecast mortality through 2035 in the context of the US elimination target. Results From 1999–2022, TB IRs declined from 64.3 to 25.0 per million. AAMRs fell from 17.4 to 7.5 between 1999–2023 (AAPC = -3.36%, 95% CI: -3.72 to -2.98). Of 26,341 deaths, 62.5% were male. By 2023, AAMRs in both genders had declined by over half. CMRs decreased across all age groups, with the largest decline in those ≥ 85 years, who also had the highest rates. Asian/Pacific Islander and American Indian/Alaska Native populations consistently had the highest AAMRs, while White individuals had the lowest. All regions except the West showed steady declines. Alaska, Hawaii, California, Mississippi, and Texas had the highest AAMRs. Large metropolitan areas consistently had higher AAMRs. Most deaths were due to respiratory TB, and 65.2% occurred in inpatient hospitals. Forecasting indicated that AAMRs are projected to remain above the US elimination threshold by 2035. Conclusion TB-related mortality in the US has declined over two decades, but recent resurgence and persistent demographic and geographic disparities highlight the need for targeted interventions to achieve elimination.